Pfizer has filed two lawsuits against the metabolic-focused startup Metsera and Novo Nordisk as of Tuesday. The first suit, filed last Friday, claims that Novo Nordisk’s rival bid for Metsera is a move “to suppress competition,” Pfizer said in a press release.
Metsera could be a vital acquisition for either company. The company is developing a once-monthly injectable GLP-1RA which had strong Phase 2b results and a potential oral GLP-1 pill. For Novo, this deal would strengthen their…
